Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gabriel R. Starbeck-Miller is active.

Publication


Featured researches published by Gabriel R. Starbeck-Miller.


Journal of Experimental Medicine | 2014

IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo

Gabriel R. Starbeck-Miller; Hai-Hui Xue; John T. Harty

The signal 3 cytokines interleukin-12 and type I interferon sustain CD8 T cell division by prolonging expression of CD25 in vivo.


Immunotherapy | 2011

Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions.

Jeffrey C. Nolz; Gabriel R. Starbeck-Miller; John T. Harty

Trafficking of CD8 T cells, in both the steady-state and during episodes of infection or inflammation, is a highly dynamic process and involves a variety of receptor-ligand interactions. A thorough, mechanistic understanding of how this process is regulated could potentially lead to disease prevention strategies, through either enhancing (for infectious diseases or tumors) or limiting (for autoimmunity) recruitment of antigen-specific CD8 T cells to areas of tissue inflammation. As CD8 T cells transition from naive to effector to memory cells, changes in gene expression will ultimately dictate anatomical localization of these cells in vivo. In this article, we discuss recent advances in understanding how antigenic stimulation influences expression of various trafficking receptors and ligands, and how this determines the tissue localization of CD8 T cells.


Journal of Immunology | 2014

Tim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infection

Jacob V. Gorman; Gabriel R. Starbeck-Miller; Nhat Long L Pham; Geri L. Traver; Paul B. Rothman; John T. Harty; John D. Colgan

T cell Ig and mucin domain (Tim) 3 is a surface molecule expressed throughout the immune system that can mediate both stimulatory and inhibitory effects. Previous studies have provided evidence that Tim-3 functions to enforce CD8 T cell exhaustion, a dysfunctional state associated with chronic stimulation. In contrast, the role of Tim-3 in the regulation of CD8 T cell responses to acute and transient stimulation remains undefined. To address this knowledge gap, we examined how Tim-3 affects CD8 T cell responses to acute Listeria monocytogenes infection. Analysis of wild-type (WT) mice infected with L. monocytogenes revealed that Tim-3 was transiently expressed by activated CD8 T cells and was associated primarily with acquisition of an effector phenotype. Comparison of responses to L. monocytogenes by WT and Tim-3 knockout (KO) mice showed that the absence of Tim-3 significantly reduced the magnitudes of both primary and secondary CD8 T cell responses, which correlated with decreased IFN-γ production and degranulation by Tim-3 KO cells stimulated with peptide Ag ex vivo. To address the T cell–intrinsic role of Tim-3, we analyzed responses to L. monocytogenes infection by WT and Tim-3 KO TCR-transgenic CD8 T cells following adoptive transfer into a shared WT host. In this setting, the accumulation of CD8 T cells and the generation of cytokine-producing cells were significantly reduced by the lack of Tim-3, demonstrating that this molecule has a direct effect on CD8 T cell function. Combined, our results suggest that Tim-3 can mediate a stimulatory effect on CD8 T cell responses to an acute infection.


European Journal of Immunology | 2011

Secondary CD8+ T‐cell responses are controlled by systemic inflammation

Thomas C. Wirth; Matthew D. Martin; Gabriel R. Starbeck-Miller; John T. Harty; Vladimir P. Badovinac

Repeated infections and experimental prime‐boost regimens frequently result in the generation of secondary (2°) CD8+ T‐cell responses. In contrast to primary (1°) CD8+ T cells, the parameters that influence the abundance and phenotype of 2° effector and memory CD8+ T‐cell populations are largely unknown. Here, we analyze the impact of different booster infections, Ag curtailment, and systemic inflammation on the quality and quantity of secondary CD8+ T‐cell responses. We show that similar to 1° CD8+ T‐cell responses, the phenotype of 2° effector and memory CD8+ T‐cell populations is critically dependent on the nature of the infectious pathogen and the inflammatory milieu early after infection. In addition, systemic inflammation increases the number of 2° effector and memory CD8+ T cells after booster infections and immunizations. Therefore, our data reveal new means to boost the number of 2° effector and memory CD8+ T cells in prime‐boost regimens and show a surprisingly high degree of plasticity in 2° memory CD8+ T‐cell phenotype that is controlled by systemic inflammation.


Journal of Immunology | 2014

Cutting Edge: Expression of FcγRIIB Tempers Memory CD8 T Cell Function In Vivo

Gabriel R. Starbeck-Miller; Vladimir P. Badovinac; Daniel L. Barber; John T. Harty

During reinfection, high-affinity IgG Abs form complexes with both soluble Ag and Ag displayed on the surface of infected cells. These interactions regulate cellular activation of both innate cells and B cells, which express specific combinations of activating FcγRs (FcγRI, FcγRIII, FcγRIV) and/or the inhibitory FcγR (FcγRIIB). Direct proof for functional expression of FcγR by Ag-specific CD8 T cells is lacking. In this article, we show that the majority of memory CD8 T cells generated by bacterial or viral infection express only FcγRIIB, and that FcγRIIB could be detected on previously activated human CD8 T cells. Of note, FcγR stimulation during in vivo Ag challenge not only inhibited the cytotoxicity of memory CD8 T cells against peptide-loaded or virus-infected targets, but FcγRIIB blockade during homologous virus challenge enhanced the secondary CD8 T cell response. Thus, memory CD8 T cells intrinsically express a functional FcγRIIB, permitting Ag–Ab complexes to regulate secondary CD8 T cell responses.


PLOS Pathogens | 2015

The Timing of Stimulation and IL-2 Signaling Regulate Secondary CD8 T Cell Responses

Shaniya H. Khan; Matthew D. Martin; Gabriel R. Starbeck-Miller; Hai-Hui Xue; John T. Harty; Vladimir P. Badovinac

Abstract Memory CD8 T cells provide protection to immune hosts by eliminating pathogen-infected cells during re-infection. While parameters influencing the generation of primary (1°) CD8 T cells are well established, the factors controlling the development of secondary (2°) CD8 T cell responses remain largely unknown. Here, we address the mechanisms involved in the generation and development of 2° memory (M) CD8 T cells. We observed that the time at which 1° M CD8 T cells enter into immune response impacts their fate and differentiation into 2° M CD8 T cells. Late-entry of 1° M CD8 T cells into an immune response (relative to the onset of infection) not only facilitated the expression of transcription factors associated with memory formation in 2° effector CD8 T cells, but also influenced the ability of 2° M CD8 T cells to localize within the lymph nodes, produce IL-2, and undergo Ag-driven proliferation. The timing of stimulation of 1° M CD8 T cells also impacted the duration of expression of the high-affinity IL-2 receptor (CD25) on 2° effector CD8 T cells and their sensitivity to IL-2 signaling. Importantly, by blocking or enhancing IL-2 signaling in developing 2° CD8 T cells, we provide direct evidence for the role of IL-2 in controlling the differentiation of Ag-driven 2° CD8 T cell responses. Thus, our data suggest that the process of 1° M to 2° M CD8 T cell differentiation is not fixed and can be manipulated, a notion with relevance for the design of future prime-boost vaccination approaches.


Journal of Immunology | 2016

Manipulating Memory CD8 T Cell Numbers by Timed Enhancement of IL-2 Signals

Marie T. Kim; Samarchith P. Kurup; Gabriel R. Starbeck-Miller; John T. Harty

As a result of the growing burden of tumors and chronic infections, manipulating CD8 T cell responses for clinical use has become an important goal for immunologists. In this article, we show that dendritic cell (DC) immunization coupled with relatively early (days 1–3) or late (days 4–6) administration of enhanced IL-2 signals increase peak effector CD8 T cell numbers, but only early IL-2 signals enhance memory numbers. IL-2 signals delivered at relatively late time points drive terminal differentiation and marked Bim-mediated contraction and do not increase memory T cell numbers. In contrast, early IL-2 signals induce effector cell metabolic profiles that are more conducive to memory formation. Of note, downregulation of CD80 and CD86 was observed on DCs in vivo following early IL-2 treatment. Mechanistically, early IL-2 treatment enhanced CTLA-4 expression on regulatory T cells, and CTLA-4 blockade alongside IL-2 treatment in vivo prevented the decrease in CD80 and CD86, supporting a cell-extrinsic role for CTLA-4 in downregulating B7 ligand expression on DCs. Finally, DC immunization followed by early IL-2 treatment and anti–CTLA-4 blockade resulted in lower memory CD8 T cell numbers compared with the DC+early IL-2 treatment group. These data suggest that curtailed signaling through the B7-CD28 costimulatory axis during CD8 T cell activation limits terminal differentiation and preserves memory CD8 T cell formation; thus, it should be considered in future T cell–vaccination strategies.


Advances in Experimental Medicine and Biology | 2015

The Role of Il-12 and Type I Interferon in Governing the Magnitude of CD8 T Cell Responses

Gabriel R. Starbeck-Miller; John T. Harty

Antigen-specific CD8 T cells provide an important protective role in response to infection by viruses, intracellular bacteria, and parasites. Pathogen-specific CD8 T cells render this protection by undergoing robust expansion in numbers while gaining the ability to produce cytokines and cytolytic machinery. Creating optimal CD8 T cell responses to infection can be critical for raising sufficient armament to provide protection against invading intracellular pathogens. Although CD8 T cells have protective value, many vaccine strategies tend to focus on creating productive B cell antibody responses to promote immunological protection. Even though antibody responses can be highly protective, coupling optimal CD8 T cell responses with suboptimal B cell responses could provide higher orders of protection than either one on their own. Therefore, a deeper understanding of the pathways that ultimately guide the magnitude of CD8 T cell responses is required to explore this potential therapeutic benefit. The following chapter highlights our current understanding of how inflammatory cytokines regulate the magnitude of CD8 T cell responses.


Archive | 2017

VivoMemory CD8 T Cell Function In RIIB γ Cutting Edge: Expression of Fc

L. Barber; John T. Harty; Gabriel R. Starbeck-Miller; Vladimir P. Badovinac


PLOS Pathogens | 2015

Late stimulated 1° M CD8 T cells acquire a long-term 2° M phenotype faster.

Shaniya H. Khan; Matthew D. Martin; Gabriel R. Starbeck-Miller; Hai-Hui Xue; John T. Harty; Vladimir P. Badovinac

Collaboration


Dive into the Gabriel R. Starbeck-Miller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hai-Hui Xue

Roy J. and Lucille A. Carver College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel L. Barber

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge